News - OR2805 - LARVOL VERI

almost3years

A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies (clinicaltrialsregister.eu)

P1/2, N=140, Ongoing, OncoResponse, Inc.

almost 3 years ago

New P1/2 trial • Combination therapy • Metastases

PD-L1 (Programmed death ligand 1)

Libtayo (cemiplimab-rwlc) • OR2805

over3years

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (clinicaltrials.gov)

P1/2, N=172, Recruiting, OncoResponse, Inc. | N=130 --> 172

over 3 years ago

Enrollment change • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)

docetaxel • Libtayo (cemiplimab-rwlc) • OR2805

over4years

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor (clinicaltrials.gov)

P1/2, N=130, Recruiting, OncoResponse, Inc.

over 4 years ago

Clinical • New P1/2 trial • Combination therapy • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRCA mutation

Keytruda (pembrolizumab) • Opdivo (nivolumab) • OR2805

over4years

Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages (SITC 2021)

Methods Cocultures of immunosuppressive primary human polarized M2c macrophages with autologous CD8+ T cells or phytohemagglutinin (PHA)-T cell blasts (exhausted T cells) were used to interrogate OR2805-dependent immunomodulatory responses as single agent and in combination with pembrolizumab, an anti-PD1 antibody. OR2805-treatment resulted in significant anti-tumor activity in lung cancer xenograft models in humanized mice. The pharmacology, PK, and toxicokinetic data support further development of OR2805 as an anti-cancer therapy, both as a monotherapy and in combination with CPI therapy.

over 4 years ago

Checkpoint inhibition

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)

CD163 expression

Keytruda (pembrolizumab) • OR2805

almost5years

[VIRTUAL] OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages (AACR 2021)

OR2805 reduces M2 macrophage-mediated immunosuppression and enhances anti-tumor immune responses. OR2805 treatment induces anti-tumor activity in lung cancer xenograft models in humanized mice. These data support further development of OR2805 as an anti-cancer therapy, both as a monotherapy and an addition to current CPI therapy.

almost 5 years ago

Checkpoint inhibition • IO biomarker

CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • ITGAM (Integrin, alpha M)

OR2805